Renalytix AI (GB:RENX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Renalytix AI reports a strategic shift towards commercial sales with its FDA-approved kidneyintelX.dkd test, now covered by Medicare at $950 per test. This move, alongside significant debt reduction and fresh funding of £11.8m, positions the company for profitability within two years. With kidney disease affecting millions, Renalytix aims to revolutionize early-stage diagnosis and treatment, driving both improved patient outcomes and financial stability.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
